Morley Stephanie 4
4 · Zomedica Corp. · Filed Apr 13, 2021
Insider Transaction Report
Form 4
Morley Stephanie
COO & VP of Product Dev
Transactions
- Exercise/Conversion
Common Stock, without par value
2021-04-12$0.19/sh+305,000$57,950→ 1,764,580 total - Sale
Common Stock, without par value
2021-04-12$1.16/sh−500,000$578,350→ 1,459,580 total - Sale
Common Stock, without par value
2021-04-12$1.16/sh−305,000$352,794→ 1,459,580 total - Exercise/Conversion
Stock option (right to buy)
2021-04-12−500,000→ 0 totalExercise: $0.43From: 2019-09-16Exp: 2021-09-16→ Common Stock, without par value (500,000 underlying) - Exercise/Conversion
Common Stock, without par value
2021-04-12$0.43/sh+500,000$215,000→ 1,959,580 total - Exercise/Conversion
Stock option (right to buy)
2021-04-12−305,000→ 445,000 totalExercise: $0.19Exp: 2025-03-14→ Common Stock, without par value (305,000 underlying)
Holdings
- 1,000(indirect: By daughter)
Common Stock, without par value
- 1,000(indirect: By step-son)
Common Stock, without par value
- 1,000(indirect: By step-son)
Common Stock, without par value
- 1,000(indirect: By daughter)
Common Stock, without par value
- 1,000(indirect: By step-daughter)
Common Stock, without par value
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2021.
- [F2]The option vests in 4 equal annual installments commencing March 13, 2020.